Type to search

Quell Therapeutics and Cellistic™ Enter a Strategic Collaboration to Develop an iPSC-derived Allogeneic T-regulatory (Treg) Cell Therapy Platform | Pharmtech Focus
Quell Therapeutics Raises $156 Million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform | Pharmtech Focus
Quell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineered Treg Cell Therapy | Pharmtech Focus